{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:13:00Z","timestamp":1793293980927,"version":"4.5.0"},"reference-count":51,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2019.0729","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T09:53:53Z","timestamp":1612346033000},"source":"Crossref","is-referenced-by-count":121,"title":["The Diagnosis and Treatment of Tuberculosis"],"prefix":"10.3238","author":[{"given":"Isabelle","family":"Su\u00e1rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Maria","family":"F\u00fcnger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Rademacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"F\u00e4tkenheuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Rybniker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2019,10,25]]},"reference":[{"key":"10.3238\/arztebl.2019.0729_ref1","unstructured":"WHO: Global Tuberculosis Report. 2018. www.who.int\/tb\/publications\/global_report\/en\/ (last accessed on 1 August 2019)."},{"key":"10.3238\/arztebl.2019.0729_ref2","doi-asserted-by":"crossref","unstructured":"Houben RM, Dodd PJ: The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med 2016; 13: e1002152","DOI":"10.1371\/journal.pmed.1002152"},{"key":"10.3238\/arztebl.2019.0729_ref3","unstructured":"Brodhun B, Altmann D, Hauer B, et al.: Bericht zur Epidemiologie der Tuberkulose in Deutschland f\u00fcr 2015. Robert Koch-Institut 2016. www.rki.de\/DE\/Content\/InfAZ\/T\/Tuberkulose\/Download\/TB2015.pdf (last accessed on 1 August 2019)."},{"key":"10.3238\/arztebl.2019.0729_ref4","unstructured":"Perumal N, Hauer B: Ein historisches Signal f\u00fcr den Kampf gegen Tuberkulose \u2013 Deutschland muss das Momentum nutzen. Epid Bull 2019; 11\/12: 95\u20136"},{"key":"10.3238\/arztebl.2019.0729_ref5","unstructured":"Haas W: Bericht zur Epidemiologie der Tuberkulose in Deutschland f\u00fcr 2001. 2003. www.rki.de\/DE\/Content\/InfAZ\/T\/Tuberkulose\/Download\/TB2001.pdf?__blob=publicationFile (last accessed on 1 August 2019)."},{"key":"10.3238\/arztebl.2019.0729_ref6","unstructured":"Brodhun B, Altmann D, Hauer B: Bericht zur Epidemiologie der Tuberkulose in Deutschland f\u00fcr 2017. Epidemiologisches Bulletin 2018; 1\u201399. www.rki.de\/DE\/Content\/InfAZ\/T\/Tuberkulose\/Download\/TB2017.pdf (last accessed on 1 August 2019)"},{"key":"10.3238\/arztebl.2019.0729_ref7","unstructured":"Brodhun B, Altmann D, Hauer B, et al.: Bericht zur Epidemiologie der Tuberkulose in Deutschland f\u00fcr 2016. Epidemiologisches Bulletin 2017; 1\u2013102. www.rki.de\/DE\/Content\/InfAZ\/T\/Tuberkulose\/Download\/TB2016.pdf (last accessed on 1 August 2019)."},{"key":"10.3238\/arztebl.2019.0729_ref8","doi-asserted-by":"crossref","unstructured":"Churchyard G, Kim P, Shah NS, et al.: What we know about tuberculosis transmission: an overview. J Infect Dis 2017; 216: 629\u201335","DOI":"10.1093\/infdis\/jix362"},{"key":"10.3238\/arztebl.2019.0729_ref9","doi-asserted-by":"crossref","unstructured":"Stewart GR, Robertson BD, Young DB: Tuberculosis: a problem with persistence. Nat Rev Microbiol 2003; 1: 97\u2013105","DOI":"10.1038\/nrmicro749"},{"key":"10.3238\/arztebl.2019.0729_ref10","unstructured":"WHO: Guidelines on the management of latent tuberculosis infection. 2015. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/136471\/9789241548908_eng.pdf;jsessionid=1513688E04508E6C C7FAE60613511D41?sequence=1 (last accessed on 1 September 2019)"},{"key":"10.3238\/arztebl.2019.0729_ref11","unstructured":"WHO: Latent TB Infection: Updated and consolidated guidelines for programmatic management. 2018. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/260233\/9789241550239-eng.pdf (last accessed September 1 2019)"},{"key":"10.3238\/arztebl.2019.0729_ref12","doi-asserted-by":"crossref","unstructured":"Murdaca G, Spano F, Contatore M, et al.: Infection risk associated with anti-TNF-alpha agents: a review. Expert Opin Drug Saf 2015; 14: 571\u201382","DOI":"10.1517\/14740338.2015.1009036"},{"key":"10.3238\/arztebl.2019.0729_ref13","doi-asserted-by":"crossref","unstructured":"Furin J, Cox H, Pai M: Tuberculosis. Lancet 2019; 393: 1642\u201356","DOI":"10.1016\/S0140-6736(19)30308-3"},{"key":"10.3238\/arztebl.2019.0729_ref14","doi-asserted-by":"crossref","unstructured":"Zumla A, Raviglione M, Hafner R, von Reyn CF: Tuberculosis. N Engl J Med 2013; 368: 745\u201355","DOI":"10.1056\/NEJMra1200894"},{"key":"10.3238\/arztebl.2019.0729_ref15","doi-asserted-by":"crossref","unstructured":"Gonzalez-Garcia A, Fortun J, Elorza Navas E, et al.: The changing epidemiology of tuberculosis in a Spanish tertiary hospital (1995\u20132013). Medicine (Baltimore) 2017; 96: e7219","DOI":"10.1097\/MD.0000000000007219"},{"key":"10.3238\/arztebl.2019.0729_ref16","doi-asserted-by":"crossref","unstructured":"Suarez I, Maria Funger S, Jung N, et al.: Severe disseminated tuberculosis in HIV-negative refugees. Lancet Infect Dis 2019; pii: 1473\u20133099 (19) 30162\u20138. [Epub ahead of print]","DOI":"10.1016\/S1473-3099(19)30162-8"},{"key":"10.3238\/arztebl.2019.0729_ref17","unstructured":"Bradby H, Humphris R, Newall D, Phillimore J: Public health aspects of migrant health: a review of the evidence on health status for refugees and asylum seekers in the european region. Copenhagen: WHO Regional Office for Europe; 2015. WHO Health Evidence Network Synthesis Reports. (last accessed on 1 August 2019)."},{"key":"10.3238\/arztebl.2019.0729_ref18","unstructured":"ECDC: Migrant Health: Background note to the \u2018ECDC Report on Migration and Infectious Diseases in the EU\u2019. 2009. https:\/\/ecdc.europa.eu\/sites\/portal\/files\/media\/en\/publications\/Publications\/0907_TER_Migrant_health_Background_note.pdf (last accessed on September 1 2019)"},{"key":"10.3238\/arztebl.2019.0729_ref19","unstructured":"Pfyffer G: Mycobacterium: General characteristics, laboratory detection, and staining procedures. In: Murray PR, Baron EJ, Landry, ML, Jorgensen JH, Pfaller MA, eds.: Manual of clinical microbiology, 9th\u00a0edition, Washington DC: American Society for Microbiology Press 2007; 543\u201372."},{"key":"10.3238\/arztebl.2019.0729_ref20","unstructured":"Schaberg T, Bauer T, Brinkmann F, et al.: [Tuberculosis guideline for adults \u2013 guideline for diagnosis and treatment of tuberculosis including LTBI testing and treatment of the German Central Committee (DZK) and the German Respiratory Society (DGP)]. Pneumologie 2017; 71: 325\u201397."},{"key":"10.3238\/arztebl.2019.0729_ref21","unstructured":"WHO: Treatment of tuberculosis: guidelines\u20144th edition. World Health Organization Press 2010. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/44165\/9789241547833_eng.pdf (last accessed on 1 September 2019)."},{"key":"10.3238\/arztebl.2019.0729_ref22","unstructured":"WHO: Xpert MTB\/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. (last accessed on 1 August 2019)."},{"key":"10.3238\/arztebl.2019.0729_ref23","doi-asserted-by":"crossref","unstructured":"Im JG, Itoh H, Shim YS, et al.: Pulmonary tuberculosis: CT findings\u2014 early active disease and sequential change with antituberculous therapy. Radiology 1993; 186: 653\u201360","DOI":"10.1148\/radiology.186.3.8430169"},{"key":"10.3238\/arztebl.2019.0729_ref24","doi-asserted-by":"crossref","unstructured":"Lee KS, Im JG: CT in adults with tuberculosis of the chest: characteristic findings and role in management. Am J Roentgenol 1995; 164: 1361\u20137","DOI":"10.2214\/ajr.164.6.7754873"},{"key":"10.3238\/arztebl.2019.0729_ref25","doi-asserted-by":"crossref","unstructured":"Yeh JJ, Chen SC, Teng WB, et al.: Identifying the most infectious lesions in pulmonary tuberculosis by high-resolution multi-detector computed tomography. Eur Radiol 2010; 20: 2135\u201345","DOI":"10.1007\/s00330-010-1796-5"},{"key":"10.3238\/arztebl.2019.0729_ref26","doi-asserted-by":"crossref","unstructured":"Geng E, Kreiswirth B, Burzynski J, Schluger NW: Clinical and radiographic correlates of primary and reactivation tuberculosis: a molecular epidemiology study. JAMA 2005; 293: 2740\u20135","DOI":"10.1001\/jama.293.22.2740"},{"key":"10.3238\/arztebl.2019.0729_ref27","unstructured":"World Health Organization: WHO guidelines approved by the Guidelines Review Committee. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and Rifampicin resistance: Xpert MTB\/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children: Policy Update. Geneva: World Health Organization. 2013. www.ncbi.nlm.nih.gov\/books\/NBK258608\/pdf\/Bookshelf_NBK258608.pdf (last accessed on 1 September 2019)."},{"key":"10.3238\/arztebl.2019.0729_ref28","doi-asserted-by":"crossref","unstructured":"Nahid P, Dorman SE, Alipanah N, et al.: Official American Thoracic Society\/Centers for disease control and prevention\/infectious diseases. Society of America Clinical Practice Guidelines: Treatment of drug-susceptible tuberculosis. Clin Infect Dis 2016; 63: e147\u2013e95","DOI":"10.1093\/cid\/ciw376"},{"key":"10.3238\/arztebl.2019.0729_ref29","unstructured":"WHO: WHO treatment guidelines for drug-resistant tuberculosis (2016 update). . (last accessed on 1 August 2019)."},{"key":"10.3238\/arztebl.2019.0729_ref30","doi-asserted-by":"crossref","unstructured":"Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D: Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167: 1472\u20137","DOI":"10.1164\/rccm.200206-626OC"},{"key":"10.3238\/arztebl.2019.0729_ref31","doi-asserted-by":"crossref","unstructured":"Ormerod LP, Horsfield N: Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis 1996; 77: 37\u201342","DOI":"10.1016\/S0962-8479(96)90073-8"},{"key":"10.3238\/arztebl.2019.0729_ref32","doi-asserted-by":"crossref","unstructured":"Gulbay BE, Gurkan OU, Yildiz OA, et al.: Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med 2006; 100: 1834\u201342","DOI":"10.1016\/j.rmed.2006.01.014"},{"key":"10.3238\/arztebl.2019.0729_ref33","doi-asserted-by":"crossref","unstructured":"Sharma SK, Singla R, Sarda P, et al.: Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010; 50: 833\u20139","DOI":"10.1086\/650576"},{"key":"10.3238\/arztebl.2019.0729_ref34","doi-asserted-by":"crossref","unstructured":"Kass JS, Shandera WX: Nervous system effects of antituberculosis therapy. CNS drugs 2010; 24: 655\u201367","DOI":"10.2165\/11534340-000000000-00000"},{"key":"10.3238\/arztebl.2019.0729_ref35","doi-asserted-by":"crossref","unstructured":"Cantini F, Nannini C, Niccoli L, et al.: Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev 2015; 14: 503\u20139","DOI":"10.1016\/j.autrev.2015.01.011"},{"key":"10.3238\/arztebl.2019.0729_ref36","doi-asserted-by":"crossref","unstructured":"Mikulska M, Lanini S, Gudiol C, et al.: ESCMID Study Group for Infections in Compromised Hosts (ESGICH). Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect 2018; 24 (Suppl 2): 71\u201382","DOI":"10.1016\/j.cmi.2018.02.003"},{"key":"10.3238\/arztebl.2019.0729_ref37","doi-asserted-by":"crossref","unstructured":"Winthrop KL, Mariette X, Silva JT, et al.: ESCMID Study Group for Infections in Compromised Hosts (ESGICH). Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 2018; 24 (Suppl 2): 21\u201340","DOI":"10.1016\/j.cmi.2018.02.002"},{"key":"10.3238\/arztebl.2019.0729_ref38","doi-asserted-by":"crossref","unstructured":"Epstein DJ, Dunn J, Deresinski S: Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management. Open Forum Infect Dis 2018; 5: 174","DOI":"10.1093\/ofid\/ofy174"},{"key":"10.3238\/arztebl.2019.0729_ref39","doi-asserted-by":"crossref","unstructured":"van Cutsem G, Isaakidis P, Farley J, Nardell E, Volchenkov G, Cox H: Infection control for drug-resistant tuberculosis: early diagnosis and treatment is the key. Clin Infect Dis 2016; 62 (Suppl 3): 238\u201343","DOI":"10.1093\/cid\/ciw012"},{"key":"10.3238\/arztebl.2019.0729_ref40","doi-asserted-by":"crossref","unstructured":"Ellis PK, Martin WJ, Dodd PJ: CD4 count and tuberculosis risk in HIV-positive adults not on ART: a systematic review and meta-analysis. Peer J 2017; 5: e4165","DOI":"10.7717\/peerj.4165"},{"key":"10.3238\/arztebl.2019.0729_ref41","doi-asserted-by":"crossref","unstructured":"Yorke E, Atiase Y, Akpalu J, Sarfo-Kantanka O, Boima V, Dey ID: The bidirectional relationship between tuberculosis and diabetes. Tuberc Res Treat 2017; 2017: 1702578","DOI":"10.1155\/2017\/1702578"},{"key":"10.3238\/arztebl.2019.0729_ref42","doi-asserted-by":"crossref","unstructured":"Rogerson TE, Chen S, Kok J, et al.: Tests for latent tuberculosis in people with ESRD: a systematic review. Am J Kidney Dis 2013; 61: 33\u201343","DOI":"10.1053\/j.ajkd.2012.07.019"},{"key":"10.3238\/arztebl.2019.0729_ref43","doi-asserted-by":"crossref","unstructured":"Odone A, Tillmann T, Sandgren A, et al.: Tuberculosis among migrant populations in the European Union and the European Economic Area. Eur J Public Health 2015; 25: 506\u201312","DOI":"10.1093\/eurpub\/cku208"},{"key":"10.3238\/arztebl.2019.0729_ref44","doi-asserted-by":"crossref","unstructured":"Getahun H, Gunneberg C, Granich R, Nunn P: HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis 2010; 50 (Suppl 3): 201\u20137","DOI":"10.1086\/651492"},{"key":"10.3238\/arztebl.2019.0729_ref45","unstructured":"UNAIDS: Joint United Nations Programme on HIV\/AIDS. www.unaids.org\/en (last accessed on 29 August 2019)."},{"key":"10.3238\/arztebl.2019.0729_ref46","doi-asserted-by":"crossref","unstructured":"Karo B, Haas W, Kollan C, et al.: Tuberculosis among people living with HIV\/AIDS in the German ClinSurv HIV Cohort: long-term incidence and risk factors. BMC Infect Dis 2014; 14: 148","DOI":"10.1186\/1471-2334-14-148"},{"key":"10.3238\/arztebl.2019.0729_ref47","doi-asserted-by":"crossref","unstructured":"Aabye MG, Ravn P, PrayGod G, et al.: The impact of HIV infection and CD4 cell count on the performance of an interferon gamma release assay in patients with pulmonary tuberculosis. PLoS One 2009; 4: e4220","DOI":"10.1371\/journal.pone.0004220"},{"key":"10.3238\/arztebl.2019.0729_ref48","doi-asserted-by":"crossref","unstructured":"Telisinghe L, Amofa-Sekyi M, Maluzi K, et al.: The sensitivity of the QuantiFERON((R))-TB Gold Plus assay in Zambian adults with active tuberculosis. Int J Tuberc Lung Dis 2017; 21: 690\u20136","DOI":"10.5588\/ijtld.16.0764"},{"key":"10.3238\/arztebl.2019.0729_ref49","unstructured":"University of Licerpool: Druginteractions. www.hiv-druginteractions.org. (last accessed on 29 August 2019)."},{"key":"10.3238\/arztebl.2019.0729_ref50","doi-asserted-by":"crossref","unstructured":"Seelbach-G\u00f6bel: 240. Stellungnahme des DZK in Zusammenarbeit mit FZB, DGI, DGPI, GPP, DGGG, DRG und DGMP zum Tuberkulosescreening bei Schwangeren im Kontext von \u00a7 36 (4) Infektionsschutzgesetz (IfSG). 2017","DOI":"10.1055\/s-0042-123082"},{"key":"10.3238\/arztebl.2019.0729_ref51","doi-asserted-by":"crossref","unstructured":"Feiterna-Sperling C, Brinkmann F, Adamczick C, et al.: [Consensus-based guidelines for diagnosis, prevention and treatment of tuberculosis in children and adolescents \u2013 A guideline on behalf of the German Society for Pediatric Infectious Diseases (DGPI)]. Pneumologie 2017; 71: 629\u201380","DOI":"10.1055\/s-0043-116545"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2019.0729","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T05:31:00Z","timestamp":1638768660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2019.0729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,25]]},"references-count":51,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2019.0729","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,25]]}}}